These findings suggested that PPARα agonist might play a therapeutic effect against early ANIT-induced cholestasis (0–12 h), but it showed limit therapeutic effect against late ANIT-induced cholestasis, such as 24 h after ANIT treatment. The gene discussed is PPARA; the disease is cholestasis.